10 Stocks With Monster Gains

8. Eli Lilly and Company (NYSE:LLY)

Eli Lilly soared by 10.33 percent on Wednesday to close at $1,107.12 apiece after profits last year nearly doubled on the back of strong sales from Zepbound and Mounjaro, alongside a 23 percent revenue growth guidance for 2026.

In an updated report on the same day, Eli Lilly and Company (NYSE:LLY) said that net income last year soared by 95 percent to $20.6 billion from $10.59 billion in 2024, as revenues surged by 45 percent to $65 billion from $45 billion.

In the fourth quarter alone, net income jumped by 50 percent to $6.6 billion from $4.4 billion in the same period a year earlier, while revenues increased by 43 percent to $19.29 billion from $13.5 billion, thanks to its weight loss and obesity drugs Zepbound and Mounjaro, as well as a 46 percent jump in volumes which offset the 5 percent lower prices.

Encouraged by the results, Eli Lilly and Company (NYSE:LLY) has set an $80 billion to $83 billion revenue growth guidance for 2026, or an implied growth of 23 to 28 percent from last year’s revenues. Earnings per share were pegged at $33.50 to $35.

Eli Lilly and Company (NYSE:LLY) received a maintained price target of $1,150 from Goldman Sachs, alongside a “buy” recommendation.